View Older Stories View More Recent Stories

Mar 30, 2021 08:00AM I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
Mar 29, 2021 07:00AM I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
Mar 29, 2021 07:00AM I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
Mar 24, 2021 08:00AM I-Mab to Host 2021 R&D Day
Mar 24, 2021 08:00AM I-Mab to Host 2021 R&D Day
Mar 19, 2021 04:20PM I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
Mar 19, 2021 04:20PM I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
Mar 11, 2021 08:00AM I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
Mar 11, 2021 08:00AM I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
Mar 10, 2021 08:00AM I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
Mar 10, 2021 08:00AM I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
Mar 3, 2021 08:00AM I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
Feb 25, 2021 08:27AM I-Mab Biopharma (IMAB) Reports First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
Feb 25, 2021 08:00AM I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
Feb 24, 2021 08:00AM I-Mab Announces Upcoming Participation at March Conferences
Feb 10, 2021 08:18AM I-Mab Biopharma (IMAB) Reports China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
Feb 10, 2021 08:00AM I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
Feb 9, 2021 08:00AM Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
Feb 5, 2021 05:27PM Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
Feb 5, 2021 08:17AM I-Mab Biopharma (IMAB) Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
Feb 5, 2021 08:00AM I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
Feb 4, 2021 08:13AM I-Mab Biopharma (IMAB) Reports First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
Feb 4, 2021 08:00AM I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
Feb 3, 2021 07:38AM AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
Jan 25, 2021 04:13PM I-Mab Biopharma (IMAB), MorphoSys (MOR) Report First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
Jan 25, 2021 04:05PM I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
Dec 23, 2020 08:00AM I-Mab Announces Upcoming Participation at January Conferences
Dec 14, 2020 08:00AM I-Mab Added to Nasdaq Biotechnology Index
Dec 11, 2020 08:05PM Annual Changes to the Nasdaq Biotechnology Index
Dec 4, 2020 08:05AM I-Mab Biopharma (IMAB) Reports Acceleration of Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in US & China
Dec 4, 2020 08:00AM I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China
Dec 1, 2020 04:23PM I-Mab Files Shelf Registration Statement for PIPE Investors
Dec 1, 2020 08:00AM I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
Nov 13, 2020 05:10AM I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial
Nov 11, 2020 08:06AM I-Mab Biopharma (IMAB) Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 11, 2020 08:00AM I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 9, 2020 08:29AM I-Mab Biopharma (IMAB) Announces Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab
Nov 9, 2020 08:12AM I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
Nov 5, 2020 09:00AM AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting
Oct 30, 2020 07:47AM AbbVie Reports Third-Quarter 2020 Financial Results
Sep 4, 2020 07:01AM AbbVie (ABBV), I-Mab (IMAB) Enter into Pact for Differentiated Immuno-oncology Therapy
Sep 4, 2020 07:00AM AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Sep 4, 2020 07:00AM AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Jan 29, 2020 10:00AM Citi Appointed as Depositary Bank for I-Mab’s Sponsored ADR Program
View More Recent Stories View Older Stories